ArticleCell death & disease2025

MEK5/ERK5 inhibition sensitizes NRAS-mutant melanoma to MAPK-targeted therapy by preventing Cyclin D/CDK4-mediated G1/S progression.

Rupesh Paudel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.